Record volume masks a margin recovery now running 12–18 months behind
₹1,207 Cr revenue is the highest ever, and net profit surged 67%. But management reaffirmed FY27 guidance at ₹5,500 Cr rather than raise it. The margin gap—13.1% delivered vs. 15–16% long-term target—is the real story.
Indo Count delivered its highest-ever quarterly revenue at ₹1,207 Cr (+25.9% YoY), with net profit surging 67.3% to ₹63.2 Cr. On the surface, it reads as a blowout. But the company reaffirmed FY27 revenue guidance at ₹5,500 Cr without raising it—a signal that near-term momentum masks underlying execution delays. The real story sits in the margin: 13.1% EBITDA in Q1, up 74 bps YoY but still 190–290 bps below the 15–16% long-term target that management promised two quarters ago.
₹1,207 Cr
+25.9% YoY; highest ever
13.1%
Target now 13% FY27, vs. 15–16% prior aspiration
₹387 Cr
+97% YoY; 26% of FY27 ₹1,500 Cr guidance
₹357/meter
+1.5% YoY (vs. +10% rupee depreciation)
The margin promise, and where it went
In the FY26 calls, management laid out a clear roadmap: tariff-related cost drag of 150–200 bps would be eliminated by Q1 FY27, unlocking a jump to 15–16% EBITDA margins. Instead, Q1 delivered 13.1%—a gap of 190–290 bps from that target. On the call, management attributed this to the gestation phase of new facilities (Ohio, Arizona, North Carolina capacity coming online) and product mix pressure in the core bed-linen business. Neither is wrong, but neither was unexpected either. The timeline slippage signals that the company is now several quarters behind on the margin recovery story.
The core business is masking its own headwinds
New business scaling (utility bedding and brands) is the bright spot: ₹387 Cr in Q1, annualized run rate of ~₹1,548 Cr is already 60% of the USD 275 million global target by 2028. But the core bed-linen franchise—the bread-and-butter that generates 70% of revenue—is running into pricing pushback. Bed-linen realization came in at ₹357/meter, up just 1.5% YoY, despite a 9–10% rupee depreciation and tariffs falling from 50% to 10%. That gap—between the headwind the rupee should have removed and what actually made it to pricing—is product mix drift: Indo Count is selling a higher proportion of lower-realization items. Management flagged this on the call and noted that price increases are negotiated and expected to flow through from Q2 onwards. But that's a forward-looking hedge, not a solved problem.
What management claimed vs. what holds up
Highest-ever quarterly revenue delivered
EBITDA margin on recovery trajectory; 13% guided for FY27
New business nearly tripled over the past year
US operations stable at 60–65% utilization despite NC greenfield
Bhilad facility disruption fully insured; confident to make up lost ground
Verdict summary: All supported by the numbers, but with important caveats. The margin target has shifted from 15–16% to 13% FY27; the timeline is extended, not accelerated. New business is tracking well, but at 60–65% utilization on the US greenfield (Jan 2026 ramp), there's execution risk if demand doesn't hold. Bhilad's closure (July 23–Aug 12, ~15–20 days) is insured for property and business interruption, but volume recovery will take several quarters to absorb.
What changed on this call
Three things shifted from the prior quarter's narrative:
Tariff refund upside removed. Prior bull case expected a US tariff refund benefit. Q1 clarification: nearly 80% of exports are on FOB basis (importer bears tariff), so the company expects no material financial benefit. This removes a tail case for upside.
Margin recovery timeline extended. Prior guidance: 15–16% EBITDA + 150–200 bps tariff cost elimination by Q1 FY27. Delivered: 13.1% and no cut to the long-term 15–16% target, but the path is now murkier. Management uses the word 'endeavor' repeatedly—honest, but vague.
New business trajectory confirmed on track. Q1 ₹387 Cr annualized is 60% of the $275M USD 2028 target already. This is the one genuine upgrade: execution on new capacity ramp (Ohio, Arizona, NC) is real and ahead of some expectations.
The bull case and the bear case
The bull: New business momentum is accelerating (₹387 Cr Q1, ₹1,500 Cr guided FY27 = 26% of target already captured). Revenue double from FY26 to FY28 is credible at current trajectory. FTA tailwinds (UK live, EU pending, US deal improving) will drive a structural shift—the company is positioned to gain share on tariff normalization. Long-term targets of ₹8,000 Cr CY2028 revenue + USD 275M new business are quantified and grounded in visible facility ramps. The stock is up 100.6% from its 52-week low; recovery narrative is intact.
The bear: Margin recovery is delayed 12–18 months from the plan. The gap between 13.1% delivered and 15–16% targeted is 190–290 bps—a structural headwind, not a temporary one. Product mix drag is not a one-quarter issue; it signals ongoing pricing pressure in the core business. Bhilad's 15–20 day closure will crimp Q2 volume recovery. Container availability constraints (West Asia conflict) are improving but not yet normalized; volume -3% YoY in Q1 is a drag. Management's tone on guidance ('not a magician') signals cautious near-term.
How the street is reading this
The market's first reaction was to sell: day 1 post-result, down 3.26% (delivery 48.5%, suggesting institutional buyers stepping in), day 3 still -3.44%. But by day 5, the stock recovered, closing up 9.76% from pre-result levels. Current price ₹435.1 sits above its 20-day, 50-day, and 200-day moving averages (₹412.95, ₹405.28, ₹310.99 respectively), confirming the recovery is not a one-day reversal—it's a reposturing. The stock is -6.19% from its all-time high of ₹463.8 but +100.6% off its 52-week low of ₹216.9, which is the arc of a turnaround narrative re-validating itself.
Ownership flows: FII holdings ticked up 29 bps QoQ to 10.14% (from 9.85%), and DII added 10 bps to 5.82%. Promoter remains stable at 58.74%. This is modest institutional accumulation, not a rush—consistent with the 'steady, not explosive' read on fundamentals. Bulk deals show a small trade at ₹444–₹445 (linked entity), not a signal of insider conviction or concern.
The street's takeaway: record revenue is priced in, but margin recovery is the debate. The day-5 recovery (and current positioning above key averages) suggests the market is giving the company credit for new business momentum while staying cautious on core margin recovery until Q2 delivery becomes clearer.
Risks, ranked by how much they should concern a holder
Margin recovery extending beyond FY27
High190–290 bps gap from 15–16% target signals gestation phase lasting longer than expected. If new facility ramp-up and product mix recovery take 18+ months, equity multiple re-rating is at risk.
Product mix headwind persists in core bed-linen
MediumRealization +1.5% YoY vs. 10% rupee tailwind = structural pricing pressure. Q2+ price hikes are promised but execution risk exists if customers resist or demand softens.
Bhilad disruption Q2 volume recovery
Medium15–20 day facility closure (July 23–Aug 12) is insured for property/business interruption, but production loss must be absorbed over next 2–3 quarters. Volume guidance 105–110M meters FY27 assumes normal operations by Q2+.
New facility utilization stalls below 70%
MediumOhio, Arizona, NC greenfields currently at 60–65% utilization Q1, guided to stay stable full-year. If demand doesn't accelerate, fixed cost drag persists and margin recovery is further delayed.
Container constraints extend beyond current expectations
MediumWest Asia conflict drove -3% YoY volume in Q1. While management expects normalization, geopolitical risk remains. A sustained closure of key shipping routes would hit FY27 guidance volume and realization.
What to watch next
1 · Q2 bed-linen realization and price flow-through
Management promised price increases would flow through from Q2 onwards. This is the test of whether the product mix headwind can be absorbed or if customer pushback stalls it. Watch for realization/meter data in next quarter.
2 · Bhilad operations normalization and volume recovery
The facility partially resumed Aug 12 with phased normalization expected. Q2 volume will signal whether the company can absorb the 15–20 day production loss or if it cascades into guidance miss.
3 · New facility utilization trajectory (Ohio, Arizona, NC)
Currently 60–65% stable Q1, but management's 'endeavor' to keep it there suggests upside is not yet visible. If utilization ticks to 70%+ or demand signals improve, margin recovery accelerates; if flat, gestation phase extends.
4 · FTA impact visibility on non-US revenue growth
UK FTA is live, EU pending. Management guides 20%+ non-US core revenue growth FY27 with 12–18 month ramp. Clarity on customer onboarding and order pipeline in Q2 call will validate or temper the FTA tailwind assumption.
Indo Count is executing its new business roadmap and the tariff normalization is real. Revenue scale and FTA access are credible. But the margin recovery narrative that was supposed to drive equity returns has now been delayed 12–18 months, and the core bed-linen business is running into pricing pressure that rupee depreciation and tariff cuts have not solved. This is not a broken quarter or a broken company—it's a steady execution story where near-term volatility (Bhilad, mix pressure, container constraints) will test patience before the long-term targets come into view.
The number to track from here is EBITDA margin. Watch whether Q2 realization bounces on price increases (validating the management thesis) or holds flat (signaling persistent mix drag). If margin moves materially toward the 13% full-year guidance—and shows a credible path to 15%+ in FY28—the long-term growth story becomes investable. Until then, hold is warranted; the recovery is real but not yet proven at the bottom line.
Informational and educational content only. Not investment advice.